+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • November 2023
  • Region: Global
  • The Business Research Company
  • ID: 5734940
The lung cancer drugs market size has grown rapidly in recent years. It will grow from $42.3 billion in 2023 to $47.72 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth observed in the historical period can be attributed to several key factors, including epidemiological and demographic trends, regulatory approvals, the development of healthcare infrastructure, and increased patient awareness and education.

The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $74.81 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be attributed to factors such as evolving health insurance and reimbursement policies, improvements in healthcare infrastructure and accessibility, and the opportunities presented by emerging markets. Significant trends expected in the forecast period encompass advancements in targeted therapies, the expanding use of immunotherapy, the utilization of genomic profiling, and the increasing focus on clinical trials and research within the field of healthcare.

The increasing prevalence of lung cancer serves as a significant growth driver for the lung cancer drugs market. This trend is primarily attributed to the rising incidence of lung cancer cases, which necessitates the development and availability of drugs for efficient and rapid disease treatment. Consequently, the industry maintains a robust drug pipeline to address this growing demand. As of January 2023, the American Cancer Society reported an estimated 238,340 new lung cancer cases, with 127,070 deaths from lung cancer expected in the same year. These figures indicate the increasing prevalence of lung cancer, thus fueling the expansion of the lung cancer drugs market.

The primary disease categories within the lung cancer drugs sector are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is characterized by rapid growth in lung tissues and often presents with metastasis beyond the lungs at the time of diagnosis. It has a higher likelihood of recurrence after treatment compared to other lung cancer types. Various drugs are used in the treatment of these cancers, including Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, and others. These drugs find application in healthcare settings such as hospitals, clinics, and other medical facilities.

The lung cancer drugs market research report is one of a series of new reports that provides lung cancer drugs market statistics, including lung cancer drugs industry, global lung cancer drugs market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth of the lung cancer drugs market is further propelled by the increasing prevalence of smoking. Smoking, a leading cause of lung cancer, is linked to inhaling and exhaling fumes from burning plant material, particularly tobacco in various forms like cigarettes, cigars, or pipes. Smoking contributes to approximately 90% of lung cancer risk in men and 70 to 80% in women. In May 2023, the Centers for Disease Control and Prevention reported that nearly 11.5% of American adults aged 18 and older were current smokers in 2021, totaling an estimated 28.3 million adult smokers in the USA. Smoking-induced conditions affect more than 16 million Americans, emphasizing the role of smoking in driving the growth of the lung cancer drugs market.

Despite the growth opportunities, the lung cancer drugs market faces limitations due to the increasing use of biologics and targeted therapies. Conventional chemical lung cancer drugs are known to cause numerous side effects and have toxic effects on the body. Their lack of cell specificity results in harm to both cancer-infected and normal cells. In contrast, biologic drugs offer highly targeted therapies with minimal to no side effects. Clinical studies have demonstrated the greater success probability of biologic drugs over traditional chemical drugs. For instance, lung cancer biologic drugs like Cetuximab, Gefitinib, and Afatinib specifically target mutated tumor cells without harming normal body cells.

The lung cancer drugs market is witnessing an emerging trend in targeted drug therapy in combination with other treatment modalities. This approach involves the utilization of immunotherapy drugs alongside other therapies like chemotherapy to enhance early diagnosis, prevention, and treatment of lung cancer. Leading pharmaceutical manufacturers are actively developing targeted drug therapies to improve the diagnostic and treatment processes for lung cancer. For instance, Merck and Co. have introduced pembrolizumab, a drug that boosts the immune system's ability to identify and combat cancer cells when used in conjunction with chemotherapy. This combination therapy has demonstrated promising outcomes in the management of lung cancer, and it is prominently marketed under the brand name Keytruda.

Major companies operating in the lung cancer drugs market are placing a strong emphasis on the introduction of novel drugs and obtaining regulatory approvals to gain a competitive advantage. The approval of new drugs is a comprehensive process involving requests from pharmaceutical manufacturers or their representatives to regulatory agencies such as the US Food and Drug Administration (FDA). This request is made for the final utilization and commercialization of a new drug for specific indications. As an illustration, in November 2022, Regeneron Pharmaceuticals Inc., a prominent biotechnology firm, announced the FDA's approval of the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for use in combination with platinum-based chemotherapy as the first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC). This approval encompasses patients with locally or metastatically advanced malignancies that are not amenable to definitive chemoradiation or surgical excision. Furthermore, this combination treatment is suitable for patients regardless of histology or PD-L1 expression.

The FDA's regulatory guidelines for lung cancer drugs are delineated in the Code of Federal Regulations (CFR), specifically under Title 21, encompassing subparts from 'A' to 'I'. Subpart 'E' focuses on procedures intended to facilitate the development, assessment, and marketing of drugs designed to treat individuals with life-threatening conditions like lung cancer. These regulations include guidelines for the oversight and evaluation of clinical trials involving lung cancer drugs and other cancer treatments by agency officials. These evaluations aim to determine the safety, efficacy, and comparative benefits of new therapies when compared to existing treatments. Compliance with these FDA regulations is a mandatory requirement for all drug manufacturers in the realm of lung cancer drugs. Consequently, these regulations play a pivotal role in overseeing the activities of lung cancer drug manufacturers and ensuring adherence to rigorous safety and efficacy standards.

Major companies operating in the lung cancer drugs market include Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, Shanghai Jinhe Bio-Technology Co. Ltd., Nlyte Software, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Biogen Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Jazz Pharmaceuticals PLC, Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC

North America was the largest region in the lung cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Lung Cancer Drugs Market Characteristics3. Lung Cancer Drugs Market Trends And Strategies
4. Lung Cancer Drugs Market - Macro Economic Scenario
4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market
5. Global Lung Cancer Drugs Market Size and Growth
5.1. Global Lung Cancer Drugs Market Drivers and Restraints
5.1.1. Drivers Of The Market
5.1.2. Restraints Of The Market
5.2. Global Lung Cancer Drugs Historic Market Size and Growth, 2018 2023, Value ($ Billion)
5.3. Global Lung Cancer Drugs Forecast Market Size and Growth, 2023 2028, 2033F, Value ($ Billion)
6. Lung Cancer Drugs Market Segmentation
6.1. Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Gemzar
  • Paraplatin
  • Taxotere
  • Navelbine
  • Avastin
  • Tarceva
  • Iressa
  • Other Drugs
6.2. Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Small cell lung cancer (SCLC)
  • Non-small cell lung cancer (NSCLC)
6.3. Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End-Users
7. Lung Cancer Drugs Market Regional And Country Analysis
7.1. Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Lung Cancer Drugs Market
8.1. Asia-Pacific Lung Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Lung Cancer Drugs Market
9.1. China Lung Cancer Drugs Market Overview
9.2. China Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Lung Cancer Drugs Market
10.1. India Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Lung Cancer Drugs Market
11.1. Japan Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Lung Cancer Drugs Market
12.1. Australia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Lung Cancer Drugs Market
13.1. Indonesia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Lung Cancer Drugs Market
14.1. South Korea Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Lung Cancer Drugs Market
15.1. Western Europe Lung Cancer Drugs Market Overview
15.2. Western Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Lung Cancer Drugs Market
16.1. UK Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Lung Cancer Drugs Market
17.1. Germany Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Lung Cancer Drugs Market
18.5. France Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Lung Cancer Drugs Market
19.9. Italy Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Lung Cancer Drugs Market
20.13. Spain Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Lung Cancer Drugs Market
21.1. Eastern Europe Lung Cancer Drugs Market Overview
21.2. Eastern Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Lung Cancer Drugs Market
22.1. Russia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Lung Cancer Drugs Market
23.1. North America Lung Cancer Drugs Market Overview
23.2. North America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Lung Cancer Drugs Market
24.1. USA Lung Cancer Drugs Market Overview
24.2. USA Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Lung Cancer Drugs Market
25.1. Canada Lung Cancer Drugs Market Overview
25.2. Canada Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Lung Cancer Drugs Market
26.1. South America Lung Cancer Drugs Market Overview
26.2. South America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Lung Cancer Drugs Market
27.1. Brazil Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Lung Cancer Drugs Market
28.1. Middle East Lung Cancer Drugs Market Overview
28.2. Middle East Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Lung Cancer Drugs Market
29.1. Africa Lung Cancer Drugs Market Overview
29.2. Africa Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Lung Cancer Drugs Market Competitive Landscape And Company Profiles
30.1. Lung Cancer Drugs Market Competitive Landscape
30.2. Lung Cancer Drugs Market Company Profiles
30.2.1. Bristol-Myers Squibb Company
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Merck & Co. Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. F. Hoffmann-La Roche Ltd.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Novartis AG
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Pfizer Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Lung Cancer Drugs Market Competitive Benchmarking32. Global Lung Cancer Drugs Market Competitive Dashboard33. Key Mergers And Acquisitions In The Lung Cancer Drugs Market
34. Lung Cancer Drugs Market Future Outlook and Potential Analysis
34.1 Lung Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Lung Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Lung Cancer Drugs Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer

Executive Summary

Lung Cancer Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • All data from the report will also be delivered in an excel dashboard format.

Description:

Where is the largest and fastest growing market for lung cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

  • Markets Covered: 1) By Drugs: Gemzar; Paraplatin; Taxotere; Navelbine; Avastin; Tarceva; Iressa; Other Drugs; 2) By Disease Type: Small cell lung cancer (SCLC); Non-small cell lung cancer (NSCLC); 3) By End User: Hospitals; Clinics; Other End-Users
  • Companies Mentioned: Bristol-Myers Squibb Company; Merck & Co. Inc.; F. Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Celgene Corporation
  • Mylan N.V.
  • Ono Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Ziopharm Oncology Inc.
  • Menarini Group
  • AstraZeneca PLC
  • Shanghai Jinhe Bio-Technology Co. Ltd.
  • Nlyte Software
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Clovis Oncology Inc.
  • Eisai Co. Ltd.
  • Exelixis Inc.
  • Genentech Inc.
  • Gilead Sciences Inc.
  • Incyte Corporation
  • Ipsen Biopharmaceuticals Inc.
  • Jazz Pharmaceuticals plc
  • Karyopharm Therapeutics Inc.
  • Kyowa Kirin Co. Ltd.
  • Loxo Oncology Inc.
  • MedImmune LLC

Methodology

Loading
LOADING...